

QUARTERLY INTEGRATED FILING (GOVERNANCE)

Compliance Report on Corporate Governance to be submitted by a listed entity on a quarterly basis

1. Name of the Listed Entity: **Infosys Limited**

2. Quarter ending: **June 30, 2026**

I. Composition of Board of Directors												
Title (Mr./ Ms.)	Name of the Director	PAN^s & DIN	Category (Chairperson /Executive/non-executive/in dependent/ Nominee) &	Initial Date of Appoint ment	Date of Re-appoint ment	Date of Cessa tion	Ten ure*	Date of Birth	No. of directorship in listed entities including this listed entity [with reference to Reg 17A]	No. of Independent Directorship in listed entities including this listed entity [with reference to proviso to reg 17A(1)] & reg. 17A(2)]	No. of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Reg 26(1) of the LODR)	No. of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Reg 26(1) of the LODR)
Mr.	Nandan Nilekani	0004 1245	Chairperson-Non-Executive-Non-Independent	24-Aug-2017			NA	02-Jun-1955	1	0	0	0
Mr.	Salil Parekh	0187 6159	Executive-Managing Director & Chief Executive Officer	02-Jan-2018	01-July-2022		NA	05-Jun-1964	1	0	0	0
Mr.	D. Sundaram	0001 6304	Non-Executive-Independent	14-Jul-2017	14-Jul-2022		108	16-Apr-1953	3	2	8	3
Mr.	Michael Nelson Gibbs	0817 7291	Non-Executive-Independent	13-Jul-2018	13-Jul-2021		96	08-Nov-1957	1	1	2	1
Mr.	Bobby Kanubhai Parikh	0001 9437	Non-Executive-Independent	15-Jul-2020	15-Jul-2023		72	30-Apr-1964	4	3	7	3
Ms.	Chitra Nayak	0910 1763	Non-Executive-Independent	25-Mar-2021	25-Mar-2024		63	09-Apr-1963	1	1	1	0
Mr.	Govind Iyer	0016 9343	Non-Executive-Independent	12-Jan-2023			42	22-Sept-1962	1	1	0	0
Ms.	Helene Auriol Potier	1016 6891	Non-Executive-Independent	26-May-2023	26-May-2026		37	26-Nov-1962	1	1	0	0

Mr.	Nitin Paranjpe	0004 5204	Non-Executive-Independent	01-Jan-2024			30	04-Mar-1963	2	1	1	0
Ms.	Diane Enberg Jurgens	1158 5200	Non-Executive-Independent	22-Apr-2026			03	21-Sep-1962	1	1	0	0

Note: Nitin Paranjpe was appointed as Vice Chairman of the Board effective April 30, 2026.

Whether Regular chairperson appointed	Yes
Whether Chairperson is related to managing director or CEO	No
^s PAN number of any director would not be displayed on the website of Stock Exchange ^{&} Category of directors means executive/non-executive/independent/Nominee. If a director fits into more than one category write all categories separating them with hyphen [*] to be filled only for Independent Director. Tenure would mean total period from which Independent director is serving on Board of directors of the listed entity in continuity without any cooling off period.	

II. Composition of Committees					
Name of Committee	Whether Regular chairperson appointed	Name of Committee members	Category (Chairperson/Executive/Non-Executive/independent/ Nominee)^{&}	Date of Appointment	Date of Cessation
1. Audit Committee	Yes	1. Bobby Kanubhai Parikh	Chairperson-Non-Executive-Independent	16-Jul-2020	
		2. D. Sundaram	Non-Executive-Independent	14-Jul-2017	
		3. Michael Nelson Gibbs	Non-Executive-Independent	04-Feb-2020	
		4. Nitin Paranjpe	Non-Executive-Independent	16-Apr-2025	
2. Nomination & Remuneration Committee	Yes	1. D. Sundaram	Chairperson-Non-Executive-Independent	14-Jul-2017	
		2. Michael Nelson Gibbs	Non-Executive-Independent	21-Apr-2020	
		3. Govind Iyer	Non-Executive-Independent	13-Jan-2023	
		4. Nitin Paranjpe	Non-Executive-Independent	01-Jan-2024	
3. Risk Management Committee	Yes	1. D. Sundaram	Chairperson-Non-Executive-Independent	14-Jul-2017	
		2. Michael Nelson Gibbs	Non-Executive-Independent	13-Jul-2018	
		3. Bobby Kanubhai Parikh	Non-Executive-Independent	16-Jul-2020	
		4. Chitra Nayak	Non-Executive-Independent	25-Mar-2021	
		5. Govind Iyer	Non-Executive-Independent	13-Jan-2023	
		6. Helene Auriol Potier	Non-Executive-Independent	17-Jun-2023	
		7. Nitin Paranjpe	Non-Executive-Independent	01-Jan-2024	
4. Stakeholders Relationship Committee	Yes	1. Michael Nelson Gibbs	Chairperson-Non-Executive-Independent	23-Mar-2023	
		2. D. Sundaram	Non-Executive-Independent	21-Apr-2020	

		3. Bobby Kanubhai Parikh	Non-Executive-Independent	14-Jan-2021	
		4. Chitra Nayak	Non-Executive-Independent	25-Mar-2021	
5. Corporate Social Responsibility Committee	Yes	1. Govind Iyer	Chairperson-Non-Executive-Independent	13-Jan-2023	
		2. Chitra Nayak	Non-Executive-Independent	25-Mar-2021	
		3. Michael Nelson Gibbs	Non-Executive-Independent	20-Apr-2023	
6. Environmental Social and Governance Committee	Yes	1. Chitra Nayak	Chairperson-Non-Executive-Independent	14-Apr-2021	
		2. Govind Iyer	Non-Executive-Independent	13-Jan-2023	
		3. Helene Auriol Potier	Non-Executive-Independent	17-Jun-2023	

&Category of directors means executive/non-executive/independent/Nominee. if a director fits into more than one category write all categories separating them with hyphen

III. Meeting of Board of Directors					
Date(s) of Meeting in the relevant quarter	Whether requirement of Quorum met*	Number of Directors present*	Number of independent directors present*	Date(s) of Meeting in the previous quarter	Maximum gap between any two consecutive meetings (in number of days)
April 23, 2026	Yes	10	8	January 14, 2026 and March 25, 2026	69 days
April 30, 2026	Yes	10	8		
* to be filled in only for the current quarter meetings Note – The Board meeting concluded on April 23, 2026, was held over two days, i.e. April 22, 2026 and April 23, 2026.					

IV. Meeting of Committees						
Name of the Committee	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	Number of Directors present	Number of independent directors' present	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days
Audit Committee	April 23, 2026	Yes	4	4	January 14, 2026 and March 25, 2026	69 days
Nomination & Remuneration Committee	April 23, 2026	Yes	4	4	January 14, 2026	98 days
	April 30, 2026	Yes	4	4		
Risk Management Committee	April 15, 2026	Yes	6	6	January 8, 2026	96 days
Stakeholders Relationship Committee	April 16, 2026	Yes	4	4	January 7, 2026	98 days

Corporate Social Responsibility Committee	April 16, 2026	Yes	3	3	January 8, 2026	97 days
Environmental Social and Governance Committee	April 16, 2026	Yes	3	3	January 7, 2026	98 days
Note – 1. The Audit Committee meeting concluded on April 23, 2026, was held over two days, i.e. April 22, 2026 and April 23, 2026. 2. The Nomination & Remuneration Committee meeting concluded on April 23, 2026, was held over two days, i.e. April 22, 2026 and April 23, 2026.						

Annexure 1		
V. Affirmations		
Sr. No.	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	Yes
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

INVESTOR GRIEVANCE REDRESSAL REPORT

Investor Grievance Redressal Report	
No. of investor complaints pending at the beginning of Quarter	1
No. of investor complaints received during the Quarter	31
No. of investor complaints disposed off during the Quarter	32

No. of investor complaints those remaining unresolved at the end of the Quarter	0
---	---

DETAILS OF CYBER SECURITY INCIDENTENCE

Whether as per Regulation 27(2) (ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter	No
Date of the event	Brief details of the event
NA	NA

DISCLOSURE OF ACQUISITION OF SHARES OR VOTING RIGHTS IN UNLISTED COMPANIES

The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below:

S. No.	Name of the unlisted company in which shares or voting rights have been acquired	Date of acquisition	Aggregate holding (% shares or voting rights) as at the end of the previous quarter	% shares or voting rights acquired during the quarter	Aggregate holding (% shares or voting rights) as at the end of the quarter
1	Agillos E-commerce Private Limited (Aerchain)	07-04-2026*	0.0%	5.31%	5.31%
2	4baseCare Precision Healthcare Private Limited	13-04-2026	4.05%	2.24%	6.29%
3	Team8 Capital III, L.P.	13-04-2026	0.00%	1.32%	1.32%
4	Indivi AG	12-05-2026	0.00%	1.57%	1.57%
5	NinjaTech AI, Inc.#	01-06-2026	0.00%	0.00%	0.00%
6	GalaxEye Space Solutions Private Limited	10-06-2026	4.55%	2.93%	7.48%

Note: **Infosys' recent investments as part of Infosys Innovation Fund:**

1. Aerchain (<https://aerchain.io/>), AI-driven sourcing & procurement startup.

Enterprises are unlocking AI value to build smarter sourcing & procurement function. Infosys is at the forefront, bringing AI-powered deeptech solutions to forward-thinking organizations across industries to create a more resilient, informed, and strategic capabilities that gives global corporations an edge in the market. Infosys Innovation Fund's investment in Aerchain brings the power of Infosys' ecosystem to co-create next-gen solutions making sourcing seamless, data-driven, and future ready. Infosys will transform organizations to accelerate AI-powered value creation and redefine procurement excellence, together with Aerchain.

*Agreements were signed in the preceding quarter (25-03-2026); and the corresponding shares were received during the current quarter.

2. 4baseCare (www.4basecare.com), AI powered precision oncology startup.

Personalized treatment based on advanced genomic and comprehensive clinical information can enhance cancer-outcomes significantly. The population specific datasets powered by tech-driven AI and Analytics solutions has immense potential to improve cancer diagnosis, treatment, drug discovery and development across Healthcare and Life Sciences ecosystem. 4baseCare develops cutting-edge precision oncology solutions, using advanced genomics and next-gen digital health technology, to personalize patient care in oncology. 4baseCare has developed a unique set of comprehensive genomic panels which allows oncologists to choose the optimal targeted therapy for their patients. 4baseCare is focused on advanced analytics and AI to enhance data-driven treatment recommendations, while expanding the presence across Asia and the Middle East. Infosys Innovation Fund's follow-on investment (invested initially in Dec 2024) further strengthens co-creation of next-generation solutions bringing the power of innovation to help Infosys' clients across Healthcare and Life Sciences industry.

3. Team8 (<https://team8.vc>), a global VC firm investing in startups across AI, Cyber Security, Software, Fintech and Digital Health.

Infosys commits to invest as a Limited Partner in Team8 as part of Infosys Innovation Fund. Team8 is an early-stage VC fund focused on AI, Cyber Security, Software, Fintech and Digital Health. Backed by a team of serial entrepreneurs, industry leaders and domain experts building a strong system from incubation to investments, Team8 brings corporate partners and startups together to solve most pressing problems with structured partnership programs. Infosys Innovation Fund to partner with Team8's ecosystem and startups to complement Infosys' capabilities, and jointly co-create next-generation solutions bringing the power of AI, Cyber Security to help Infosys' clients navigate their business transformation.

4. Indivi (<https://indivi.io>), Switzerland based TechBio startup for neuroscience drug development.

Neuroscience has an R&D constraint as the probability of technical and regulatory success is exceptionally low. The ability to measure impact of treatment in a slow progressing and heterogeneous neuroscience disease makes effect detection of the treatment extremely challenging. At the same time, a global epidemic of age-related neuroscience diseases is on a significant rise globally, resulting in pressure on the healthcare systems. Life Sciences companies are investing billions in R&D and clinical trials. The convergence of technological progress (sensor, radiomics, AI/ML, compute, quantum, sequencing) and data creates an opportunity to transform medicine development (patient-centric self-measurement, deep phenotyping of disease, tech-derived biomarkers/endpoints, AI-based companion diagnostics and predictive maintenance, reverse translational discovery). Indivi is a digital bio-marker platform specialist enhancing the success rate drug development in neuroscience. Infosys Innovation Fund's investment in Indivi brings the power of Infosys' ecosystem to co-create next-gen solutions to unlock value for clients across Healthcare and Life Sciences industry.

5 NinjaTech AI (www.ninjatech.ai), US based personal Agentic AI startup.

AI has potential to unlock significant opportunities for enterprises. However, evolving AI capabilities and enterprise needs require effective execution. NinjaTech's personal agentic AI is autonomous, self-evolving, and interacts with other agentic AI and humans. Infosys Innovation Fund's investment brings the power of client and business context in amplifying the Human + AI model in AI execution to unlock business value. #Investment is in Simple Agreement for Future Equity (SAFE), ownership % will be determined post conversion.

6 GalaxEye (<https://galaxeye.space>), SpaceTech startup.

SpaceTech is a frontier technology with potential to unlock significant value to businesses globally and create high impact solutions at scale. GalaxEye, builds multi-sensor (Synthetic Aperture Radar + Multi Spectral Imaging) satellites and synchronization platform generating comprehensive all-weather, high-resolution and intuitive datasets. Infosys Innovation Fund's follow-on investment (invested initially in 2024) in GalaxEye further strengthens co-creation of next-generation solutions bringing the power of AI and SpaceTech innovation to help clients navigate their business transformation.

DISCLOSURE OF IMPOSITION OF FINE OR PENALTY

The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:

S. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or	Details of the violation(s)/contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed
--------	-----------------------	--	---	---	--

			any other communication from the authority		entity, quantifiable in monetary terms to the extent possible
1.	Pennsylvania Department of Revenue, USA	Order passed/ action taken. Penalty – USD 1,791.33	April 1, 2026	Penalty due to amendment of returns filed for the past quarters.	None, there is no material impact on financials, operations or other activities of the Company.
2.	Ministry of Commerce	Order passed/ action taken. Penalty – SAR 12,000	April 6, 2026	Penalty for late lodgment of financial statement for CY 2023	None, there is no material impact on financials, operations or other activities of the Company.
3.	State of Delaware, USA	Order passed/ action taken. Penalty – USD 48.52	April 18, 2026	Notice pertaining to withholding filing for the period ending 31st December 2024	None, there is no material impact on financials, operations or other activities of the Company.
4.	Georgia Department of Revenue	Order passed/ action taken. Penalty – USD 50	April 27, 2026	Penalty pertaining to withholding payroll tax	None, there is no material impact on financials, operations or other activities of the Company.
5.	Inland Revenue Department, Hong Kong	Order passed/ action taken. Penalty – HKD 6681	May 4, 2026	Surcharge notice for overdue tax	None, there is no material impact on financials, operations or other activities of the Company.
6.	Department of Labor and Workforce Development – State of New Jersey	Order passed/ action taken. Penalty – USD 282.73	May 8, 2026	Penalty pertaining to tax to be paid for Q2FY24, Q3FY24, Q3FY25 and Q4FY25	None, there is no material impact on financials, operations or other activities of the Company.
7.	City of Birmingham, Department of Finance	Order passed/ action taken. Penalty – USD 183.49	May 12, 2026	Penalty levied due to late payment of local taxes	None, there is no material impact on financials, operations or other activities of the Company.
8.	Employment Security Department, Washington State, USA	Order passed/ action taken. Penalty – USD 250	May 14, 2026	Penalty due to missing hours and SOC codes in Unemployment Tax and Wage report for Q1FY26	None, there is no material impact on financials, operations or other activities of the Company.
9.	Michigan Department of Treasury	Order passed/ action taken. Penalty – USD 24,348.39	May 27, 2026	Penalty due to alleged underpayment of state withholding tax for Q12026	None, there is no material impact on financials, operations or other activities of the Company.
10.	Government of the District of Columbia, Department of Employment Services	Order passed/ action taken. Penalty – USD 100	June 2, 2026	Notice received for Late Payment Penalty related to Outstanding Contribution and Wage Report for Tax Period January 2026	None, there is no material impact on financials, operations or other activities of the Company.
11.	Georgia Department of Revenue	Order passed/ action taken.	June 11, 2026	Penalty pertaining to tax liability for Q4FY25	None, there is no material impact on financials,

		Penalty – USD 60			operations or other activities of the Company.
12.	Department of Finance, Denver	Order passed/ action taken. Penalty – USD 124.31	June 17, 2026	Penalty due to alleged underpayment of tax	None, there is no material impact on financials, operations or other activities of the Company.
13.	Mauritius Revenue Authority	Order passed/ action taken. Penalty – MUR 1,170,975	June 29, 2026	Penalty due to alleged short payment of tax for FY2023	None, there is no material impact on financials, operations or other activities of the Company.

DISCLOSURE OF UPDATES TO ONGOING TAX LITIGATIONS OR DISPUTES

The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:

S. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation / dispute
-	-	-	-	-

This report was placed before the Board of Directors in their meeting held on July 23, 2026 and there were no specific observations.

Name: A.G.S Manikantha
Designation: Company Secretary
Membership no: ACS21918